Peptide Synthesis Market by Reagents (Resins, Amino Acid, Dyes), Instruments (Peptide Synthesizer, Chromatography, Lyophilizer), Technique (Solid-phase, Solution-phase, Hybrid), Services, Application (Therapeutics), End User - Global Forecast to 2029
The global peptide synthesis market is projected to surpass USD 1.41 billion in 2029 from USD 0.81 billion in 2024, with a significant CAGR of 11.7%. The peptide synthesis market is driven by several factors such as advancements in technology, increasing research in drug discovery, and the growing demand for personalized medicine. Additionally, the rising prevalence of chronic diseases such as cancer and diabetes is fueling demand for therapeutic peptides in targeted therapies further propelling the growth of the market.
“Resins and Amino acids accounted for the dominant share in the reagents market”
Based on offerings (products & services), products (Consumables and Instruments), consumables (Reagents and Other Consumables), Reagents (Resins, Amino Acids, Coupling Reagents, Dyes and Fluorescent Labelling Reagents, Deprotection Reagents, Cleavage Reagents and Other Reagents), Instruments (Peptide Synthesizers (automated and manual), Chromatography Equipment, Lyophilizers and Others). Resins form the foundation of solid-phase peptide synthesis (SPPS), serving as a stable platform for the stepwise construction of peptide chains. Advancements in resins such as preloaded resins and specialized linkers are likely to impact positively on the market.
“Peptide synthesis services dominated the market”
The services segment is further segmented into peptide library synthesis, peptide synthesis, peptide purification services, and peptide analysis services. Peptide synthesis services dominated the market due to their ability to meet the increasing demand for custom and complex peptides required in drug discovery, therapeutic development, and research applications. Additionally, the rise of personalized medicine and peptide-based vaccines has increased the demand for custom synthesis driving the segmental growth.
“Therapeutics segment dominated the application segment in 2023”
Applications segment is divided into Therapeutics, Diagnostics and Research & Development. Therapeutics by Indications (Cancer, Diabetes, Obesity, Autoimmune Disease and Other Disease Indication), Therapeutics by Molecules (Peptide-Based Vaccines, Peptide-Drug Conjugates (PDCs), Peptide Inhibitors and Other Molecules). Advancements in peptide synthesis technologies, such as solid-phase peptide synthesis (SPPS) and recombinant DNA methods, has enabled the efficient production of high-purity, cost-effective peptides for vaccine development. The growing focus on personalized immunotherapies and increased investment in peptide-based vaccine research further reinforce their leading position in the market.
“North America: the largest share of the peptide synthesis market”
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the peptide synthesis market in 2023 and is estimated to continue dominance during the forecast period. US leads the North American market, driven by the strong presence of key players like Thermo Fisher Scientific and CEM Corporation, with substantial funding for biomedical research and innovation in peptide-based therapeutics. Europe holds a significant share of the market, with countries like Germany, and UK being major contributors. This dominance attributed to strong R&D activities, collaborations between academic institutions and industry, and a growing focus on personalized medicine and peptide-based drugs.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the peptide synthesis market.
The primary interviews conducted for this report can be categorized as follows:
Research Coverage:
This research report categorizes the peptide synthesis market offerings (products & services), products (Consumables and Instruments), consumables (Reagents and Other Consumables), Reagents (Resins, Amino Acids, Coupling Reagents, Dyes and Fluorescent Labelling Reagents, Deprotection Reagents, Cleavage Reagents and Other Reagents), Instruments (Peptide Synthesizers (automated and manual), Chromatography Equipment, Lyophilizers and Others). Services (Peptide Library Synthesis, Peptide Synthesis, Peptide Purification Services and Peptide Analysis Services), Technique (Chemical (Solid Phase Peptide Synthesis, Solution Phase peptide synthesis and Other Chemical Methods and Biological (Recombinant DNA Technology and Enzymes), Applications (Therapeutics, Diagnostics and Research & Development), Therapeutics by Indications (Cancer, Diabetes, Obesity, Autoimmune Disease and Other Disease Indication), Therapeutics by Molecules (Peptide-Based Vaccines, Peptide-Drug Conjugates (PDCs), Peptide Inhibitors and Other Molecules), End User (Pharmaceutical and biotechnology companies, CDMOs & CROs, Academic & Research Institutes, Medical Device Companies and Hospitals and Diagnostic Centers). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the peptide synthesis market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the peptide synthesis market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the peptide synthesis and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
“Resins and Amino acids accounted for the dominant share in the reagents market”
Based on offerings (products & services), products (Consumables and Instruments), consumables (Reagents and Other Consumables), Reagents (Resins, Amino Acids, Coupling Reagents, Dyes and Fluorescent Labelling Reagents, Deprotection Reagents, Cleavage Reagents and Other Reagents), Instruments (Peptide Synthesizers (automated and manual), Chromatography Equipment, Lyophilizers and Others). Resins form the foundation of solid-phase peptide synthesis (SPPS), serving as a stable platform for the stepwise construction of peptide chains. Advancements in resins such as preloaded resins and specialized linkers are likely to impact positively on the market.
“Peptide synthesis services dominated the market”
The services segment is further segmented into peptide library synthesis, peptide synthesis, peptide purification services, and peptide analysis services. Peptide synthesis services dominated the market due to their ability to meet the increasing demand for custom and complex peptides required in drug discovery, therapeutic development, and research applications. Additionally, the rise of personalized medicine and peptide-based vaccines has increased the demand for custom synthesis driving the segmental growth.
“Therapeutics segment dominated the application segment in 2023”
Applications segment is divided into Therapeutics, Diagnostics and Research & Development. Therapeutics by Indications (Cancer, Diabetes, Obesity, Autoimmune Disease and Other Disease Indication), Therapeutics by Molecules (Peptide-Based Vaccines, Peptide-Drug Conjugates (PDCs), Peptide Inhibitors and Other Molecules). Advancements in peptide synthesis technologies, such as solid-phase peptide synthesis (SPPS) and recombinant DNA methods, has enabled the efficient production of high-purity, cost-effective peptides for vaccine development. The growing focus on personalized immunotherapies and increased investment in peptide-based vaccine research further reinforce their leading position in the market.
“North America: the largest share of the peptide synthesis market”
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the peptide synthesis market in 2023 and is estimated to continue dominance during the forecast period. US leads the North American market, driven by the strong presence of key players like Thermo Fisher Scientific and CEM Corporation, with substantial funding for biomedical research and innovation in peptide-based therapeutics. Europe holds a significant share of the market, with countries like Germany, and UK being major contributors. This dominance attributed to strong R&D activities, collaborations between academic institutions and industry, and a growing focus on personalized medicine and peptide-based drugs.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the peptide synthesis market.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Tier 1- 45%, Tier 2- 35%, Tier 3- 20%
- By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
Research Coverage:
This research report categorizes the peptide synthesis market offerings (products & services), products (Consumables and Instruments), consumables (Reagents and Other Consumables), Reagents (Resins, Amino Acids, Coupling Reagents, Dyes and Fluorescent Labelling Reagents, Deprotection Reagents, Cleavage Reagents and Other Reagents), Instruments (Peptide Synthesizers (automated and manual), Chromatography Equipment, Lyophilizers and Others). Services (Peptide Library Synthesis, Peptide Synthesis, Peptide Purification Services and Peptide Analysis Services), Technique (Chemical (Solid Phase Peptide Synthesis, Solution Phase peptide synthesis and Other Chemical Methods and Biological (Recombinant DNA Technology and Enzymes), Applications (Therapeutics, Diagnostics and Research & Development), Therapeutics by Indications (Cancer, Diabetes, Obesity, Autoimmune Disease and Other Disease Indication), Therapeutics by Molecules (Peptide-Based Vaccines, Peptide-Drug Conjugates (PDCs), Peptide Inhibitors and Other Molecules), End User (Pharmaceutical and biotechnology companies, CDMOs & CROs, Academic & Research Institutes, Medical Device Companies and Hospitals and Diagnostic Centers). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the peptide synthesis market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the peptide synthesis market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the peptide synthesis and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (advancements in peptide therapeutics, technological advancements, growing use of peptides in diagnostics and research), restraints (Regulatory Hurdles, High cost of peptide synthesis and instruments), opportunities (Adoption of personalized medicine, Rise in strategic collaborations and partnerships) and Challenges (Addressing Immunogenicity, Environmental Concerns) influencing the growth of the market.
- Product/Service Development/Innovation: Detailed insights on upcoming technologies in peptide synthesis manufacturing, research and development activities, and new product/service launches in the peptide synthesis market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the peptide synthesis market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product & service offerings of leading players Thermo Fisher Scientific, Inc. (US), Bachem Holding AG (Switzerland), Kaneka Corporation (US), Inc. and Merck KGaA (Germany), among others.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONAL SCOPE
1.3.3 INCLUSIONS AND EXCLUSIONS
1.3.4 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY RESEARCH
2.1.2 PRIMARY RESEARCH
2.2 MARKET SIZE ESTIMATION METHODOLOGY
2.2.1 GLOBAL MARKET ESTIMATION
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
2.2.3 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
2.3 GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PEPTIDE SYNTHESIS MARKET OVERVIEW
4.2 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET,
BY PRODUCT TYPE AND COUNTRY, 2023
4.3 PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024 VS. 2029
4.4 PEPTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Advancements in peptide therapeutics
5.2.1.2 Innovations in peptide synthesis instruments
5.2.1.3 Growing use of peptides in diagnostics and research
5.2.2 RESTRAINTS
5.2.2.1 Regulatory hurdles
5.2.2.2 High cost of peptide synthesis and instruments
5.2.3 OPPORTUNITIES
5.2.3.1 Adoption of personalized medicine
5.2.3.2 Strategic collaborations and partnerships
5.2.4 CHALLENGES
5.2.4.1 Immunogenicity issues
5.2.4.2 Environmental concerns
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
5.5 SUPPLY CHAIN ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.7.1 PEPTIDE SYNTHESIS MARKET: PRODUCT MANUFACTURERS
5.7.2 PEPTIDE SYNTHESIS MARKET: SERVICE PROVIDERS
5.7.3 PEPTIDE SYNTHESIS MARKET: END USERS
5.7.4 PEPTIDE SYNTHESIS MARKET: REGULATORY BODIES
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Solid-phase peptide synthesis (SPPS)
5.9.1.2 Liquid-phase peptide synthesis (LPPS)
5.9.1.3 Enzymatic peptide synthesis
5.9.1.4 Continuous-flow peptide synthesis
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Labeling and tracking technologies
5.9.2.2 Purification techniques
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Cell-free protein synthesis
5.9.3.2 Protein design and engineering
5.10 PATENT ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 TRADE DATA FOR HS CODE 902720 (CHROMATOGRAPHS AND ELECTROPHORESIS INSTRUMENTS)
5.11.1.1 Import data for HS code 902720
5.11.1.2 Export data for HS CODE 902720
5.11.2 TRADE DATA FOR HS CODE 841933 (LYOPHILISATION APPARATUS,
FREEZE DRYING UNITS AND SPRAY DRYERS)
5.11.2.1 Import data for HS code 841993
5.11.2.2 Export data for HS code 841933
5.12 KEY CONFERENCES AND EVENTS, 2025–2026
5.13 REGULATORY LANDSCAPE
5.13.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13.2 REGULATORY FRAMEWORK
5.13.2.1 North America
5.13.2.1.1 US
5.13.2.1.2 Canada
5.13.2.2 Europe
5.13.2.2.1 Germany
5.13.2.2.2 UK
5.13.2.2.3 France
5.13.2.3 Asia Pacific
5.13.2.3.1 Japan
5.13.2.3.2 China
5.13.2.4 Latin America
5.13.2.4.1 Brazil
5.13.2.5 Middle East & Africa
5.13.2.5.1 GCC Countries
5.13.2.5.2 South Africa
5.14 PORTER’S FIVE FORCES ANALYSIS
5.14.1 BARGAINING POWER OF SUPPLIERS
5.14.2 BARGAINING POWER OF BUYERS
5.14.3 THREAT OF NEW ENTRANTS
5.14.4 THREAT OF SUBSTITUTES
5.14.5 INTENSITY OF COMPETITIVE RIVALRY
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.15.2 BUYING CRITERIA
5.16 IMPACT OF AI/GENERATIVE AI ON PEPTIDE SYNTHESIS MARKET
5.16.1 INTRODUCTION
5.16.2 IMPACT OF AI ON PEPTIDE SYNTHESIS ECOSYSTEM
5.16.3 FUTURE OF GENERATIVE AI IN PEPTIDE SYNTHESIS ECOSYSTEM
6 PEPTIDE SYNTHESIS MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 PRODUCTS
6.2.1 INCREASING ADOPTION OF SOLID AND LIQUID-PHASE PEPTIDE SYNTHESIS TO STIMULATE GROWTH
6.3 SERVICES
6.3.1 GROWING ADVANCEMENTS IN PEPTIDE DESIGN AND SYNTHESIS OPTIMIZATION TO FUEL MARKET
7 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE
7.1 INTRODUCTION
7.2 CONSUMABLES
7.2.1 REAGENTS
7.2.1.1 Resins
7.2.1.1.1 Growing demand for therapeutic peptides to boost market
7.2.1.2 Amino acids
7.2.1.2.1 Increasing advancements in synthetic amino acid modifications to aid growth
7.2.1.3 Coupling reagents
7.2.1.3.1 Rising adoption of high-throughput peptide synthesis to expedite growth
7.2.1.4 Dyes & fluorescent labeling reagents
7.2.1.4.1 Increasing demand for high-resolution, sensitive imaging technologies to promote growth
7.2.1.5 Deprotection reagents
7.2.1.5.1 Rising complexity of modified peptides and cyclic structures to facilitate growth
7.2.1.6 Cleavage reagents
7.2.1.6.1 Increasing use of complex peptides to sustain growth
7.2.1.7 Other reagents
7.2.2 OTHER CONSUMABLES
7.3 INSTRUMENTS
7.3.1 PEPTIDE SYNTHESIZERS
7.3.1.1 Automated peptide synthesizers
7.3.1.1.1 Increasing launches of automated peptide synthesizers to promote growth
7.3.1.2 Manual peptide synthesizers
7.3.1.2.1 Growing use of peptide synthesizers for early-stage drug discovery and research to fuel market
7.3.2 CHROMATOGRAPHY SYSTEMS
7.3.2.1 Increasing shift toward high-throughput and industrial-scale peptide production to amplify growth
7.3.3 LYOPHILIZERS
7.3.3.1 Rising influence of contract manufacturing organizations to encourage growth
7.3.4 OTHER INSTRUMENTS
8 PEPTIDE SYNTHESIS SERVICES MARKET, BY TYPE
8.1 INTRODUCTION
8.2 PEPTIDE SYNTHESIS
8.2.1 RISING ADOPTION OF PERSONALIZED MEDICINES AND TARGETED THERAPIES TO INTENSIFY GROWTH
8.3 PEPTIDE PURIFICATION SERVICES
8.3.1 GROWING EMPHASIS ON HIGH-QUALITY PEPTIDES IN PHARMACEUTICAL DEVELOPMENT AND BIOTECH TO DRIVE MARKET
8.4 PEPTIDE LIBRARY SYNTHESIS
8.4.1 INCREASING FOCUS ON SYNTHETIC BIOLOGY TO AUGMENT GROWTH
8.5 PEPTIDE ANALYSIS SERVICES
8.5.1 INCREASING ADVANCEMENTS IN MASS SPECTROMETRY AND CHROMATOGRAPHY TO BOLSTER GROWTH
9 PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE
9.1 INTRODUCTION
9.2 CHEMICAL METHODS
9.2.1 SOLID-PHASE PEPTIDE SYNTHESIS
9.2.1.1 Increasing use of peptides and peptide derivatives in modern medicines use to encourage growth
9.2.2 LIQUID-PHASE PEPTIDE SYNTHESIS
9.2.2.1 Growing advancements in purification technologies to boost market
9.2.3 OTHER CHEMICAL METHODS
9.3 BIOLOGICAL METHODS
9.3.1 RECOMBINANT DNA TECHNOLOGY
9.3.1.1 Increasing innovations in genetic engineering and synthetic biology to drive market
9.3.2 ENZYMATIC SYNTHESIS
9.3.2.1 Growing shift toward sustainable and eco-friendly manufacturing to propel market
10 PEPTIDE SYNTHESIS MARKET, BY APPLICATION
10.1 INTRODUCTION
10.2 THERAPEUTIC APPLICATIONS
10.2.1 THERAPEUTIC APPLICATIONS, BY INDICATION
10.2.1.1 Cancer
10.2.1.1.1 Rising clinical trials to contribute to growth
10.2.1.2 Diabetes
10.2.1.2.1 Increasing need for diabetes management to favor growth
10.2.1.3 Obesity
10.2.1.3.1 Increasing development of next-generation weight management therapies to foster growth
10.2.1.4 Autoimmune diseases
10.2.1.4.1 Growing prevalence of rheumatoid arthritis, lupus,
and multiple sclerosis to fuel market
10.2.1.5 Other diseases
10.2.2 THERAPEUTIC APPLICATIONS, BY MOLECULE
10.2.2.1 Peptide-based vaccines
10.2.2.1.1 Increasing research on infectious diseases and cancer immunotherapy to augment growth
10.2.2.2 Peptide-drug conjugates
10.2.2.2.1 Growing focus of pharmaceutical companies on drug conjugation to drive market
10.2.2.3 Peptide inhibitors
10.2.2.3.1 Rising traction for precision medicine to assist growth
10.2.2.4 Other molecules
10.3 DIAGNOSTIC APPLICATIONS
10.3.1 RISE OF PERSONALIZED MEDICINE AND POINT-OF-CARE TESTING TO ACCELERATE GROWTH
10.4 DISCOVERY & DEVELOPMENT APPLICATIONS
10.4.1 GROWING ADVANCEMENTS IN COMBINATORIAL CHEMISTRY AND
HIGH-THROUGHPUT PEPTIDE LIBRARIES TO DRIVE MARKET
11 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER
11.1 INTRODUCTION
11.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
11.2.1 INCREASING RESEARCH ON GENOMICS AND MOLECULAR BIOLOGY TO EXPEDITE GROWTH
11.3 CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS
11.3.1 SHIFT TOWARD CUSTOM AND MODIFIED PEPTIDES TO DRIVE MARKET
11.4 ACADEMIC & RESEARCH INSTITUTES
11.4.1 INCREASING FINANCIAL AND REGULATORY SUPPORT FOR RESEARCH TO SUPPORT GROWTH
11.5 MEDICAL DEVICE COMPANIES
11.5.1 BOOMING PEPTIDE-BASED DRUG DELIVERIES TO PROMOTE GROWTH
11.6 HOSPITALS & DIAGNOSTIC CENTERS
11.6.1 RISING DEMAND FOR PEPTIDE-BASED DIAGNOSTICS TO FAVOR GROWTH
12 PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER
12.1 INTRODUCTION
12.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
12.2.1 INCREASING FOCUS ON PEPTIDE-BASED THERAPEUTICS IN ONCOLOGY AND METABOLIC DISORDERS TO INTENSIFY GROWTH
12.3 MEDICAL DEVICE COMPANIES
12.3.1 NEED TO DETECT INFECTIOUS DISEASES, CANCER, AND METABOLIC DISORDERS TO AID GROWTH
12.4 HOSPITALS & DIAGNOSTIC CENTERS
12.4.1 RISING USE OF PEPTIDE BIOMARKERS TO SUPPORT GROWTH
12.5 ACADEMIC & RESEARCH INSTITUTES
12.5.1 GROWING FOCUS ON DRUG DESIGN, VACCINE DEVELOPMENT,
AND CANCER RESEARCH TO BOOST MARKET
12.6 CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS
12.6.1 INCREASING DEMAND FOR COST-EFFECTIVE PEPTIDE SYNTHESIS SERVICES TO FACILITATE GROWTH
13 PEPTIDE SYNTHESIS MARKET, BY REGION
13.1 INTRODUCTION
13.2 NORTH AMERICA
13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
13.2.2 US
13.2.2.1 Well-developed healthcare and research infrastructure to aid growth
13.2.3 CANADA
13.2.3.1 Increasing government funding for advanced drugs to amplify growth
13.3 EUROPE
13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
13.3.2 GERMANY
13.3.2.1 Germany to hold largest market share in Europe
13.3.3 UK
13.3.3.1 Increasing peptide synthesis research to contribute to growth
13.3.4 FRANCE
13.3.4.1 Favorable government initiatives to augment growth
13.3.5 ITALY
13.3.5.1 Growing public and private sector investments to propel market
13.3.6 SPAIN
13.3.6.1 Rising focus on advanced therapies to expedite growth
13.3.7 REST OF EUROPE
13.4 ASIA PACIFIC
13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
13.4.2 CHINA
13.4.2.1 Expanding biopharma sector to advance growth
13.4.3 JAPAN
13.4.3.1 Growing geriatric population to fuel market
13.4.4 INDIA
13.4.4.1 Increasing investments and developments in biotechnology to favor growth
13.4.5 SOUTH KOREA
13.4.5.1 Booming biotechnology sector to amplify growth
13.4.6 AUSTRALIA
13.4.6.1 Increasing government funding and initiatives to augment growth
13.4.7 REST OF ASIA PACIFIC
13.5 LATIN AMERICA
13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
13.5.2 BRAZIL
13.5.2.1 Growing interest in peptide-based drugs to fuel market
13.5.3 MEXICO
13.5.3.1 Increasing initiatives for stem cell research and regenerative medicine projects to foster growth
13.5.4 REST OF LATIN AMERICA
13.6 MIDDLE EAST
13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
13.6.2 GCC COUNTRIES
13.6.2.1 Saudi Arabia
13.6.2.1.1 Increasing government-backed investments for infrastructure to aid growth
13.6.2.2 UAE
13.6.2.2.1 High prevalence of diabetes and cardiovascular diseases to augment growth
13.6.2.3 Rest of GCC Countries
13.6.3 REST OF MIDDLE EAST
13.7 AFRICA
13.7.1 INCREASING INVESTMENTS IN PHARMACEUTICAL INFRASTRUCTURE AND LIFE SCIENCE INNOVATIONS TO BOOST MARKET
13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
14 COMPETITIVE LANDSCAPE
14.1 OVERVIEW
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021–2025
14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN PEPTIDE SYNTHESIS MARKET
14.3 REVENUE ANALYSIS, 2019–2023
14.4 MARKET SHARE ANALYSIS, 2023
14.5 COMPANY VALUATION AND FINANCIAL METRICS
14.5.1 COMPANY VALUATION
14.5.2 FINANCIAL METRICS
14.6 BRAND/PRODUCT COMPARISON
14.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
14.7.1 STARS
14.7.2 EMERGING LEADERS
14.7.3 PERVASIVE PLAYERS
14.7.4 PARTICIPANTS
14.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
14.7.5.1 Company footprint
14.7.5.2 Region footprint
14.7.5.3 Offering footprint
14.7.5.4 Technique footprint
14.7.5.5 Application footprint
14.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
14.8.1 PROGRESSIVE COMPANIES
14.8.2 RESPONSIVE COMPANIES
14.8.3 DYNAMIC COMPANIES
14.8.4 STARTING BLOCKS
14.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
14.8.5.1 Detailed list of key startups/SMEs
14.8.5.2 Competitive benchmarking of startups/SMEs
14.9 COMPETITIVE SCENARIO
14.9.1 PRODUCT LAUNCHES
14.9.2 DEALS
14.9.3 EXPANSIONS
15 COMPANY PROFILES
15.1 KEY PLAYERS
15.1.1 THERMO FISHER SCIENTIFIC INC.
15.1.1.1 Business overview
15.1.1.2 Products/Services offered
15.1.1.3 Recent developments
15.1.1.3.1 Product launches
15.1.1.4 MnM view
15.1.1.4.1 Key strengths
15.1.1.4.2 Strategic choices
15.1.1.4.3 Weaknesses and competitive threats
15.1.2 MERCK KGAA
15.1.2.1 Business overview
15.1.2.2 Products/Services offered
15.1.2.3 MnM view
15.1.2.3.1 Key strengths
15.1.2.3.2 Strategic choices
15.1.2.3.3 Weaknesses and competitive threats
15.1.3 AGILENT TECHNOLOGIES, INC.
15.1.3.1 Business overview
15.1.3.2 Products/Services offered
15.1.3.3 MnM view
15.1.3.3.1 Key strengths
15.1.3.3.2 Strategic choices
15.1.3.3.3 Weaknesses and competitive threats
15.1.4 GENSCRIPT
15.1.4.1 Business overview
15.1.4.2 Products/Services offered
15.1.4.3 Recent developments
15.1.4.3.1 Expansions
15.1.4.4 MnM view
15.1.4.4.1 Key strengths
15.1.4.4.2 Strategic choices
15.1.4.4.3 Weaknesses and competitive threats
15.1.5 KANEKA CORPORATION
15.1.5.1 Business overview
15.1.5.2 Products/Services offered
15.1.5.3 Recent developments
15.1.5.3.1 Expansions
15.1.5.4 MnM view
15.1.5.4.1 Key strengths
15.1.5.4.2 Strategic choices
15.1.5.4.3 Weaknesses and competitive threats
15.1.6 BACHEM
15.1.6.1 Business overview
15.1.6.2 Products/Services offered
15.1.6.3 Recent developments
15.1.6.3.1 Deals
15.1.7 SYNGENE INTERNATIONAL LIMITED
15.1.7.1 Business overview
15.1.7.2 Products/Services offered
15.1.8 MESA LABS, INC.
15.1.8.1 Business overview
15.1.8.2 Products/Services offered
15.1.8.3 Recent developments
15.1.8.3.1 Product launches
15.1.8.3.2 Deals
15.1.9 BIOTAGE
15.1.9.1 Business overview
15.1.9.2 Products/Services offered
15.1.10 CEM CORPORATION
15.1.10.1 Business overview
15.1.10.2 Products/Services offered
15.1.10.3 Recent developments
15.1.10.3.1 Product launches
15.1.10.3.2 Deals
15.1.11 DALTON PHARMA SERVICES
15.1.11.1 Business overview
15.1.11.2 Products/Services offered
15.1.12 BIO-SYNTHESIS INC.
15.1.12.1 Business overview
15.1.12.2 Products/Services offered
15.1.13 CSBIO
15.1.13.1 Business overview
15.1.13.2 Products/Services offered
15.1.14 PROTEOGENIX
15.1.14.1 Business overview
15.1.14.2 Products/Services offered
15.1.15 INNOVAGEN AB
15.1.15.1 Business overview
15.1.15.2 Products/Services offered
15.1.16 BIOSYNTH
15.1.16.1 Business overview
15.1.16.2 Products/Services offered
15.1.16.2.1 Deals
15.2 OTHER PLAYERS
15.2.1 AURIGENE PHARMACEUTICAL SERVICES LTD.
15.2.2 CORDENPHARMA
15.2.3 JPT PEPTIDE TECHNOLOGIES
15.2.4 PUROLITE
15.2.5 BIOMATIK
15.2.6 CPC SCIENTIFIC INC.
15.2.7 ADVANCED CHEMTECH, INC.
15.2.8 AMBIOPHARM INC.
15.2.9 LUXEMBOURG BIO TECHNOLOGIES
15.2.10 AAPPTEC
15.2.11 ANYGEN
15.2.12 CHEMPEP
15.2.13 PROTEOGENIX
16 APPENDIX
16.1 DISCUSSION GUIDE
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
16.3 CUSTOMIZATION OPTIONS
16.4 RELATED REPORTS
16.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONAL SCOPE
1.3.3 INCLUSIONS AND EXCLUSIONS
1.3.4 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY RESEARCH
2.1.2 PRIMARY RESEARCH
2.2 MARKET SIZE ESTIMATION METHODOLOGY
2.2.1 GLOBAL MARKET ESTIMATION
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
2.2.3 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
2.3 GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PEPTIDE SYNTHESIS MARKET OVERVIEW
4.2 NORTH AMERICA: PEPTIDE SYNTHESIS MARKET,
BY PRODUCT TYPE AND COUNTRY, 2023
4.3 PEPTIDE SYNTHESIS MARKET, BY OFFERING, 2024 VS. 2029
4.4 PEPTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Advancements in peptide therapeutics
5.2.1.2 Innovations in peptide synthesis instruments
5.2.1.3 Growing use of peptides in diagnostics and research
5.2.2 RESTRAINTS
5.2.2.1 Regulatory hurdles
5.2.2.2 High cost of peptide synthesis and instruments
5.2.3 OPPORTUNITIES
5.2.3.1 Adoption of personalized medicine
5.2.3.2 Strategic collaborations and partnerships
5.2.4 CHALLENGES
5.2.4.1 Immunogenicity issues
5.2.4.2 Environmental concerns
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
5.5 SUPPLY CHAIN ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.7.1 PEPTIDE SYNTHESIS MARKET: PRODUCT MANUFACTURERS
5.7.2 PEPTIDE SYNTHESIS MARKET: SERVICE PROVIDERS
5.7.3 PEPTIDE SYNTHESIS MARKET: END USERS
5.7.4 PEPTIDE SYNTHESIS MARKET: REGULATORY BODIES
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Solid-phase peptide synthesis (SPPS)
5.9.1.2 Liquid-phase peptide synthesis (LPPS)
5.9.1.3 Enzymatic peptide synthesis
5.9.1.4 Continuous-flow peptide synthesis
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Labeling and tracking technologies
5.9.2.2 Purification techniques
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Cell-free protein synthesis
5.9.3.2 Protein design and engineering
5.10 PATENT ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 TRADE DATA FOR HS CODE 902720 (CHROMATOGRAPHS AND ELECTROPHORESIS INSTRUMENTS)
5.11.1.1 Import data for HS code 902720
5.11.1.2 Export data for HS CODE 902720
5.11.2 TRADE DATA FOR HS CODE 841933 (LYOPHILISATION APPARATUS,
FREEZE DRYING UNITS AND SPRAY DRYERS)
5.11.2.1 Import data for HS code 841993
5.11.2.2 Export data for HS code 841933
5.12 KEY CONFERENCES AND EVENTS, 2025–2026
5.13 REGULATORY LANDSCAPE
5.13.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13.2 REGULATORY FRAMEWORK
5.13.2.1 North America
5.13.2.1.1 US
5.13.2.1.2 Canada
5.13.2.2 Europe
5.13.2.2.1 Germany
5.13.2.2.2 UK
5.13.2.2.3 France
5.13.2.3 Asia Pacific
5.13.2.3.1 Japan
5.13.2.3.2 China
5.13.2.4 Latin America
5.13.2.4.1 Brazil
5.13.2.5 Middle East & Africa
5.13.2.5.1 GCC Countries
5.13.2.5.2 South Africa
5.14 PORTER’S FIVE FORCES ANALYSIS
5.14.1 BARGAINING POWER OF SUPPLIERS
5.14.2 BARGAINING POWER OF BUYERS
5.14.3 THREAT OF NEW ENTRANTS
5.14.4 THREAT OF SUBSTITUTES
5.14.5 INTENSITY OF COMPETITIVE RIVALRY
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.15.2 BUYING CRITERIA
5.16 IMPACT OF AI/GENERATIVE AI ON PEPTIDE SYNTHESIS MARKET
5.16.1 INTRODUCTION
5.16.2 IMPACT OF AI ON PEPTIDE SYNTHESIS ECOSYSTEM
5.16.3 FUTURE OF GENERATIVE AI IN PEPTIDE SYNTHESIS ECOSYSTEM
6 PEPTIDE SYNTHESIS MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 PRODUCTS
6.2.1 INCREASING ADOPTION OF SOLID AND LIQUID-PHASE PEPTIDE SYNTHESIS TO STIMULATE GROWTH
6.3 SERVICES
6.3.1 GROWING ADVANCEMENTS IN PEPTIDE DESIGN AND SYNTHESIS OPTIMIZATION TO FUEL MARKET
7 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE
7.1 INTRODUCTION
7.2 CONSUMABLES
7.2.1 REAGENTS
7.2.1.1 Resins
7.2.1.1.1 Growing demand for therapeutic peptides to boost market
7.2.1.2 Amino acids
7.2.1.2.1 Increasing advancements in synthetic amino acid modifications to aid growth
7.2.1.3 Coupling reagents
7.2.1.3.1 Rising adoption of high-throughput peptide synthesis to expedite growth
7.2.1.4 Dyes & fluorescent labeling reagents
7.2.1.4.1 Increasing demand for high-resolution, sensitive imaging technologies to promote growth
7.2.1.5 Deprotection reagents
7.2.1.5.1 Rising complexity of modified peptides and cyclic structures to facilitate growth
7.2.1.6 Cleavage reagents
7.2.1.6.1 Increasing use of complex peptides to sustain growth
7.2.1.7 Other reagents
7.2.2 OTHER CONSUMABLES
7.3 INSTRUMENTS
7.3.1 PEPTIDE SYNTHESIZERS
7.3.1.1 Automated peptide synthesizers
7.3.1.1.1 Increasing launches of automated peptide synthesizers to promote growth
7.3.1.2 Manual peptide synthesizers
7.3.1.2.1 Growing use of peptide synthesizers for early-stage drug discovery and research to fuel market
7.3.2 CHROMATOGRAPHY SYSTEMS
7.3.2.1 Increasing shift toward high-throughput and industrial-scale peptide production to amplify growth
7.3.3 LYOPHILIZERS
7.3.3.1 Rising influence of contract manufacturing organizations to encourage growth
7.3.4 OTHER INSTRUMENTS
8 PEPTIDE SYNTHESIS SERVICES MARKET, BY TYPE
8.1 INTRODUCTION
8.2 PEPTIDE SYNTHESIS
8.2.1 RISING ADOPTION OF PERSONALIZED MEDICINES AND TARGETED THERAPIES TO INTENSIFY GROWTH
8.3 PEPTIDE PURIFICATION SERVICES
8.3.1 GROWING EMPHASIS ON HIGH-QUALITY PEPTIDES IN PHARMACEUTICAL DEVELOPMENT AND BIOTECH TO DRIVE MARKET
8.4 PEPTIDE LIBRARY SYNTHESIS
8.4.1 INCREASING FOCUS ON SYNTHETIC BIOLOGY TO AUGMENT GROWTH
8.5 PEPTIDE ANALYSIS SERVICES
8.5.1 INCREASING ADVANCEMENTS IN MASS SPECTROMETRY AND CHROMATOGRAPHY TO BOLSTER GROWTH
9 PEPTIDE SYNTHESIS MARKET, BY TECHNIQUE
9.1 INTRODUCTION
9.2 CHEMICAL METHODS
9.2.1 SOLID-PHASE PEPTIDE SYNTHESIS
9.2.1.1 Increasing use of peptides and peptide derivatives in modern medicines use to encourage growth
9.2.2 LIQUID-PHASE PEPTIDE SYNTHESIS
9.2.2.1 Growing advancements in purification technologies to boost market
9.2.3 OTHER CHEMICAL METHODS
9.3 BIOLOGICAL METHODS
9.3.1 RECOMBINANT DNA TECHNOLOGY
9.3.1.1 Increasing innovations in genetic engineering and synthetic biology to drive market
9.3.2 ENZYMATIC SYNTHESIS
9.3.2.1 Growing shift toward sustainable and eco-friendly manufacturing to propel market
10 PEPTIDE SYNTHESIS MARKET, BY APPLICATION
10.1 INTRODUCTION
10.2 THERAPEUTIC APPLICATIONS
10.2.1 THERAPEUTIC APPLICATIONS, BY INDICATION
10.2.1.1 Cancer
10.2.1.1.1 Rising clinical trials to contribute to growth
10.2.1.2 Diabetes
10.2.1.2.1 Increasing need for diabetes management to favor growth
10.2.1.3 Obesity
10.2.1.3.1 Increasing development of next-generation weight management therapies to foster growth
10.2.1.4 Autoimmune diseases
10.2.1.4.1 Growing prevalence of rheumatoid arthritis, lupus,
and multiple sclerosis to fuel market
10.2.1.5 Other diseases
10.2.2 THERAPEUTIC APPLICATIONS, BY MOLECULE
10.2.2.1 Peptide-based vaccines
10.2.2.1.1 Increasing research on infectious diseases and cancer immunotherapy to augment growth
10.2.2.2 Peptide-drug conjugates
10.2.2.2.1 Growing focus of pharmaceutical companies on drug conjugation to drive market
10.2.2.3 Peptide inhibitors
10.2.2.3.1 Rising traction for precision medicine to assist growth
10.2.2.4 Other molecules
10.3 DIAGNOSTIC APPLICATIONS
10.3.1 RISE OF PERSONALIZED MEDICINE AND POINT-OF-CARE TESTING TO ACCELERATE GROWTH
10.4 DISCOVERY & DEVELOPMENT APPLICATIONS
10.4.1 GROWING ADVANCEMENTS IN COMBINATORIAL CHEMISTRY AND
HIGH-THROUGHPUT PEPTIDE LIBRARIES TO DRIVE MARKET
11 PEPTIDE SYNTHESIS PRODUCTS MARKET, BY END USER
11.1 INTRODUCTION
11.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
11.2.1 INCREASING RESEARCH ON GENOMICS AND MOLECULAR BIOLOGY TO EXPEDITE GROWTH
11.3 CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS
11.3.1 SHIFT TOWARD CUSTOM AND MODIFIED PEPTIDES TO DRIVE MARKET
11.4 ACADEMIC & RESEARCH INSTITUTES
11.4.1 INCREASING FINANCIAL AND REGULATORY SUPPORT FOR RESEARCH TO SUPPORT GROWTH
11.5 MEDICAL DEVICE COMPANIES
11.5.1 BOOMING PEPTIDE-BASED DRUG DELIVERIES TO PROMOTE GROWTH
11.6 HOSPITALS & DIAGNOSTIC CENTERS
11.6.1 RISING DEMAND FOR PEPTIDE-BASED DIAGNOSTICS TO FAVOR GROWTH
12 PEPTIDE SYNTHESIS SERVICES MARKET, BY END USER
12.1 INTRODUCTION
12.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
12.2.1 INCREASING FOCUS ON PEPTIDE-BASED THERAPEUTICS IN ONCOLOGY AND METABOLIC DISORDERS TO INTENSIFY GROWTH
12.3 MEDICAL DEVICE COMPANIES
12.3.1 NEED TO DETECT INFECTIOUS DISEASES, CANCER, AND METABOLIC DISORDERS TO AID GROWTH
12.4 HOSPITALS & DIAGNOSTIC CENTERS
12.4.1 RISING USE OF PEPTIDE BIOMARKERS TO SUPPORT GROWTH
12.5 ACADEMIC & RESEARCH INSTITUTES
12.5.1 GROWING FOCUS ON DRUG DESIGN, VACCINE DEVELOPMENT,
AND CANCER RESEARCH TO BOOST MARKET
12.6 CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS
12.6.1 INCREASING DEMAND FOR COST-EFFECTIVE PEPTIDE SYNTHESIS SERVICES TO FACILITATE GROWTH
13 PEPTIDE SYNTHESIS MARKET, BY REGION
13.1 INTRODUCTION
13.2 NORTH AMERICA
13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
13.2.2 US
13.2.2.1 Well-developed healthcare and research infrastructure to aid growth
13.2.3 CANADA
13.2.3.1 Increasing government funding for advanced drugs to amplify growth
13.3 EUROPE
13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
13.3.2 GERMANY
13.3.2.1 Germany to hold largest market share in Europe
13.3.3 UK
13.3.3.1 Increasing peptide synthesis research to contribute to growth
13.3.4 FRANCE
13.3.4.1 Favorable government initiatives to augment growth
13.3.5 ITALY
13.3.5.1 Growing public and private sector investments to propel market
13.3.6 SPAIN
13.3.6.1 Rising focus on advanced therapies to expedite growth
13.3.7 REST OF EUROPE
13.4 ASIA PACIFIC
13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
13.4.2 CHINA
13.4.2.1 Expanding biopharma sector to advance growth
13.4.3 JAPAN
13.4.3.1 Growing geriatric population to fuel market
13.4.4 INDIA
13.4.4.1 Increasing investments and developments in biotechnology to favor growth
13.4.5 SOUTH KOREA
13.4.5.1 Booming biotechnology sector to amplify growth
13.4.6 AUSTRALIA
13.4.6.1 Increasing government funding and initiatives to augment growth
13.4.7 REST OF ASIA PACIFIC
13.5 LATIN AMERICA
13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
13.5.2 BRAZIL
13.5.2.1 Growing interest in peptide-based drugs to fuel market
13.5.3 MEXICO
13.5.3.1 Increasing initiatives for stem cell research and regenerative medicine projects to foster growth
13.5.4 REST OF LATIN AMERICA
13.6 MIDDLE EAST
13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
13.6.2 GCC COUNTRIES
13.6.2.1 Saudi Arabia
13.6.2.1.1 Increasing government-backed investments for infrastructure to aid growth
13.6.2.2 UAE
13.6.2.2.1 High prevalence of diabetes and cardiovascular diseases to augment growth
13.6.2.3 Rest of GCC Countries
13.6.3 REST OF MIDDLE EAST
13.7 AFRICA
13.7.1 INCREASING INVESTMENTS IN PHARMACEUTICAL INFRASTRUCTURE AND LIFE SCIENCE INNOVATIONS TO BOOST MARKET
13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
14 COMPETITIVE LANDSCAPE
14.1 OVERVIEW
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021–2025
14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN PEPTIDE SYNTHESIS MARKET
14.3 REVENUE ANALYSIS, 2019–2023
14.4 MARKET SHARE ANALYSIS, 2023
14.5 COMPANY VALUATION AND FINANCIAL METRICS
14.5.1 COMPANY VALUATION
14.5.2 FINANCIAL METRICS
14.6 BRAND/PRODUCT COMPARISON
14.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
14.7.1 STARS
14.7.2 EMERGING LEADERS
14.7.3 PERVASIVE PLAYERS
14.7.4 PARTICIPANTS
14.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
14.7.5.1 Company footprint
14.7.5.2 Region footprint
14.7.5.3 Offering footprint
14.7.5.4 Technique footprint
14.7.5.5 Application footprint
14.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
14.8.1 PROGRESSIVE COMPANIES
14.8.2 RESPONSIVE COMPANIES
14.8.3 DYNAMIC COMPANIES
14.8.4 STARTING BLOCKS
14.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
14.8.5.1 Detailed list of key startups/SMEs
14.8.5.2 Competitive benchmarking of startups/SMEs
14.9 COMPETITIVE SCENARIO
14.9.1 PRODUCT LAUNCHES
14.9.2 DEALS
14.9.3 EXPANSIONS
15 COMPANY PROFILES
15.1 KEY PLAYERS
15.1.1 THERMO FISHER SCIENTIFIC INC.
15.1.1.1 Business overview
15.1.1.2 Products/Services offered
15.1.1.3 Recent developments
15.1.1.3.1 Product launches
15.1.1.4 MnM view
15.1.1.4.1 Key strengths
15.1.1.4.2 Strategic choices
15.1.1.4.3 Weaknesses and competitive threats
15.1.2 MERCK KGAA
15.1.2.1 Business overview
15.1.2.2 Products/Services offered
15.1.2.3 MnM view
15.1.2.3.1 Key strengths
15.1.2.3.2 Strategic choices
15.1.2.3.3 Weaknesses and competitive threats
15.1.3 AGILENT TECHNOLOGIES, INC.
15.1.3.1 Business overview
15.1.3.2 Products/Services offered
15.1.3.3 MnM view
15.1.3.3.1 Key strengths
15.1.3.3.2 Strategic choices
15.1.3.3.3 Weaknesses and competitive threats
15.1.4 GENSCRIPT
15.1.4.1 Business overview
15.1.4.2 Products/Services offered
15.1.4.3 Recent developments
15.1.4.3.1 Expansions
15.1.4.4 MnM view
15.1.4.4.1 Key strengths
15.1.4.4.2 Strategic choices
15.1.4.4.3 Weaknesses and competitive threats
15.1.5 KANEKA CORPORATION
15.1.5.1 Business overview
15.1.5.2 Products/Services offered
15.1.5.3 Recent developments
15.1.5.3.1 Expansions
15.1.5.4 MnM view
15.1.5.4.1 Key strengths
15.1.5.4.2 Strategic choices
15.1.5.4.3 Weaknesses and competitive threats
15.1.6 BACHEM
15.1.6.1 Business overview
15.1.6.2 Products/Services offered
15.1.6.3 Recent developments
15.1.6.3.1 Deals
15.1.7 SYNGENE INTERNATIONAL LIMITED
15.1.7.1 Business overview
15.1.7.2 Products/Services offered
15.1.8 MESA LABS, INC.
15.1.8.1 Business overview
15.1.8.2 Products/Services offered
15.1.8.3 Recent developments
15.1.8.3.1 Product launches
15.1.8.3.2 Deals
15.1.9 BIOTAGE
15.1.9.1 Business overview
15.1.9.2 Products/Services offered
15.1.10 CEM CORPORATION
15.1.10.1 Business overview
15.1.10.2 Products/Services offered
15.1.10.3 Recent developments
15.1.10.3.1 Product launches
15.1.10.3.2 Deals
15.1.11 DALTON PHARMA SERVICES
15.1.11.1 Business overview
15.1.11.2 Products/Services offered
15.1.12 BIO-SYNTHESIS INC.
15.1.12.1 Business overview
15.1.12.2 Products/Services offered
15.1.13 CSBIO
15.1.13.1 Business overview
15.1.13.2 Products/Services offered
15.1.14 PROTEOGENIX
15.1.14.1 Business overview
15.1.14.2 Products/Services offered
15.1.15 INNOVAGEN AB
15.1.15.1 Business overview
15.1.15.2 Products/Services offered
15.1.16 BIOSYNTH
15.1.16.1 Business overview
15.1.16.2 Products/Services offered
15.1.16.2.1 Deals
15.2 OTHER PLAYERS
15.2.1 AURIGENE PHARMACEUTICAL SERVICES LTD.
15.2.2 CORDENPHARMA
15.2.3 JPT PEPTIDE TECHNOLOGIES
15.2.4 PUROLITE
15.2.5 BIOMATIK
15.2.6 CPC SCIENTIFIC INC.
15.2.7 ADVANCED CHEMTECH, INC.
15.2.8 AMBIOPHARM INC.
15.2.9 LUXEMBOURG BIO TECHNOLOGIES
15.2.10 AAPPTEC
15.2.11 ANYGEN
15.2.12 CHEMPEP
15.2.13 PROTEOGENIX
16 APPENDIX
16.1 DISCUSSION GUIDE
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
16.3 CUSTOMIZATION OPTIONS
16.4 RELATED REPORTS
16.5 AUTHOR DETAILS
